Integrated Plans Fertile For Real-world Evidence

Area of Science:

• Health Economics
• Clinical Evidence Generation

Background:

• Insurers exhibit a cautious approach to adopting real-world evidence (RWE).
• Despite successful applications, such as in diabetes management, payer confidence in RWE remains low.
• Skepticism is amplified by consensus among respected healthcare authorities.

Purpose of the Study:

• To analyze the current stance of health insurers regarding the utilization of real-world evidence.
• To investigate the factors contributing to the pessimistic outlook of payers towards RWE.
• To understand the influence of expert opinions on the adoption of RWE by the insurance industry.

Main Methods:

• Review of current insurance policies and payer statements regarding RWE.
• Analysis of clinical case studies demonstrating RWE's impact, particularly in diabetes.
• Survey or synthesis of opinions from key healthcare stakeholders and respected voices.

Main Results:

• A prevalent 'wait-and-see' attitude among most insurers concerning RWE implementation.
• Limited perceived value of RWE by payers in informing healthcare decisions.
• Significant alignment between payer pessimism and the views of established healthcare leaders.

Conclusions:

• The widespread adoption of RWE by insurers is impeded by persistent skepticism and a lack of demonstrated value perception.
• Overcoming payer hesitancy requires robust evidence of RWE's utility and a shift in expert consensus.
• Future strategies must address both the practical application and the perceived credibility of real-world evidence in healthcare funding.